Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles

Therapeutics based on RNA interference (RNAi) have emerged as a potential new class of drugs for treating human disease by silencing the target messenger RNA (mRNA), thereby reducing levels of the corresponding pathogenic protein. The major challenge for RNAi therapeutics is the development of safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Tomoko, Butler, James S, Sehgal, Alfica, Severgnini, Mariano, Racie, Tim, Sharman, Jennifer, Ding, Feng, Morskaya, Svetlana Shulga, Brodsky, Joshua, Tchangov, Lubomir, Kosovrasti, Verbena, Meys, Mike, Nechev, Lubomir, Wang, Gang, Peng, Chang Geng, Fang, Yupang, Maier, Martin, Rajeev, Kallanthottathil G, Li, Robert, Hettinger, Julia, Barros, Scott, Clausen, Valerie, Zhang, Xuemei, Wang, Qianfan, Hutabarat, Renta, Dokholyan, Nikolay V, Wolfrum, Christian, Manoharan, Muthiah, Kotelianski, Victor, Stoffel, Markus, Sah, Dinah WY
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412494/
https://www.ncbi.nlm.nih.gov/pubmed/22850721
http://dx.doi.org/10.1038/mt.2012.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412494/
https://www.ncbi.nlm.nih.gov/pubmed/22850721
http://dx.doi.org/10.1038/mt.2012.33

Ejemplares similares